Biohaven sold its most advanced drug months before the pivotal trial reads out. That timing is the story — a company with a shrinking runway does not get to wait for good news.
More than 90% of pancreatic cancers are driven by KRAS, and KRAS was called undruggable for forty years. Median survival went from 6.7 months to 13.2.
Glioblastoma kills because surgeons cannot see every last cell. These nanoparticles make clusters half a hair’s width visible — then stay behind to destroy what the scalpel missed.
Continuous glucose monitoring transformed diabetes care. Ketones — the warning sign for a life-threatening emergency — still required a finger stick. Libre Duo puts both in one sensor.
Venture funding up 25%, eight IPOs, record lab space — and 3,605 fewer jobs. The money came back to Massachusetts biotech; the employment did not follow it.
Another large study, another 24% lower dementia rate among the vaccinated. The authors say plainly it cannot establish cause — and explain exactly why their adjustments did not close the gap.
A brief, precisely dosed exposure to a signal that normally suppresses immunity turned natural killer cells into tumour infiltrators — with no genetic engineering, which is what could make it cheap.
Existing hepatitis B drugs functionally cure about 1% of patients and must be taken indefinitely. Hibsago reached 19% in six months — and made “functional cure” a regulatory category.
One drug delivers DNA damage to the tumour; the other blocks the repair crew. The combination also tripped an innate immune alarm the researchers were not primarily aiming at.
The money arrives only when the FDA accepts the filing. Milestone-linked financing lets a biotech raise at tomorrow’s valuation rather than today’s — if tomorrow arrives.
Asthma is commoner in boys before puberty and in women after. A mouse study proposes the switch runs through male hormones building nerves in the lung — not through hormones acting on immune cells directly.
Device regulation assumes a product behaves the same way every time. Generative AI does not, and the FDA has signalled it is working out what to do about that.